First Solar: Turning CuRe into Contract Value as Policy Cloud Looms
Record Q2 margins and first CuRe adjusters signal tech inflection, but Section 232 and freight costs keep the market cautious (down 33% from peak).
FSLR · Earnings Call · 2026-07-30
A Record Quarter with a New Commercial Lever
First Solar’s Q2 2026 delivered exactly what investors want to see on the surface: record volume, expanded gross margin, and a new commercial milestone. The company reported over $1 billion in net sales and gross margin of approximately 57%, up 12 percentage points year over year, driven in part by an estimated $89 million net IEPA tariff benefit. Crucially, management announced the first customer notifications related to contract technology adjusters — meaning the CuRe product’s performance advantages are now starting to translate into backlog value, not just technical promise.
We are pleased with the performance of CuRe, with both high volume manufacturing at our Perrysburg facility and performance data from field deployments across multiple climates exceeding expectations.
The company also highlighted the revised timeline for the South Carolina finishing line, now expected to complete mid-2027 — a decision that enables earlier incorporation of CuRe technology. This is a deliberate tradeoff: sacrificing near-term capacity to bake higher-efficiency, higher-value modules into the facility’s commercial launch. Management framed it as “simplify execution, accelerate value realization.”
Policy, Hyperscalers, and the Booking Discipline
The commercial backdrop remains a tug-of-war between robust demand and unresolved policy. During the call, CEO Mark Widmar highlighted the Cypress Creek project—a 1.6 GW solar-plus-storage deal behind Google—as evidence that hyperscaler demand remains “somewhat insatiable.” The company booked ~1.9 GW in the U.S. at an average selling price of $0.36/watt, with most of that coming in July, and noted another ~2 GW of active conversations.
Yet management is deliberately holding back on full-send booking activity, awaiting clarity on Section 232 and FEOC rules. “We are still optimistic that the outcome will be constructive,” Widmar said, but he also admitted that “everybody has a view of how the construct may be” and that the industry needs policy clarity above all. The company is taking a disciplined approach—requiring cash security on new contracts and letting some counterparties sit on the sidelines.
This patience is not free. The Southeast Asia underutilization option continues to cost roughly $30 million per quarter, as CFO Alexander Bradley explained. The company is weighing whether to bring fully finished product in, add U.S. finishing capacity, or potentially idle more capacity—all tethered to the 232 outcome.
Financial Position and the Market's Cautious Appraisal
Despite the record quarter, the stock remains ~33% below its June 2026 peak, a drawdown that reflects investor anxiety over tariff drag and execution risk. The fundamentals reinforce the resilience: effective net cash stood at $2.0 billion at the end of Q1, with a strong positive trend over the past year. Management reaffirmed full-year guidance, though noted higher freight costs and a net tariff impact of $60–80 million.
Compared to earlier quarters, the emphasis has shifted from defensive contraction (managing cancellations, BP litigation) to proactive commercialization. As Widmar noted in April: “Once it gets communicated, the key will be what the impact is.” That waiting game is now the central narrative—and CuRe is the lever that could turn policy tailwinds into outsized pricing power.
The company’s ability to command $0.36/watt in a policy vacuum is a strong signal. If Section 232 lands constructively and CuRe adjusters expand across the backlog, the market may finally reward the stock’s embedded optionality. But with freight costs rising and domestic trucking now nearly as expensive as trans-Pacific shipping, operational leverage will be tested. This is a name where the story is genuinely moving—but the market is waiting for proof.